Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
44.15
-0.14 (-0.32%)
At close: May 26, 2026, 4:00 PM EDT
44.26
+0.11 (0.25%)
After-hours: May 26, 2026, 7:31 PM EDT
Sanofi Revenue
Sanofi had revenue of 11.24B EUR in the quarter ending March 31, 2026, with 6.02% growth. This brings the company's revenue in the last twelve months to 47.35B, up 2.09% year-over-year. In the year 2025, Sanofi had annual revenue of 46.72B with 5.49% growth.
Revenue (ttm)
47.35B EUR
Revenue Growth
+2.09%
P/S Ratio
1.95
Revenue / Employee
632,686 EUR
Employees
74,846
Market Cap
106.43B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 46.72B | 2.43B | 5.49% |
| Dec 31, 2024 | 44.29B | 2.67B | 6.41% |
| Dec 31, 2023 | 41.62B | 1.06B | 2.61% |
| Dec 31, 2022 | 40.56B | 1.39B | 3.54% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | 37.63B | 1.95B | 5.48% |
| Dec 31, 2018 | 35.68B | -544.00M | -1.50% |
| Dec 31, 2017 | 36.22B | 1.53B | 4.40% |
| Dec 31, 2016 | 34.70B | -165.00M | -0.47% |
| Dec 31, 2015 | 34.86B | 2.86B | 8.94% |
| Dec 31, 2014 | 32.00B | 708.00M | 2.26% |
| Dec 31, 2013 | 31.29B | -4.67B | -12.98% |
| Dec 31, 2012 | 35.96B | 899.00M | 2.56% |
| Dec 31, 2011 | 35.06B | 1.02B | 3.00% |
| Dec 31, 2010 | 34.04B | 2.80B | 8.98% |
| Dec 31, 2009 | 31.23B | 2.42B | 8.38% |
| Dec 31, 2008 | 28.82B | -390.00M | -1.34% |
| Dec 31, 2007 | 29.21B | -282.00M | -0.96% |
| Dec 31, 2006 | 29.49B | 976.00M | 3.42% |
| Dec 31, 2005 | 28.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 65.77B |
| Pfizer | 63.32B |
| AbbVie | 62.82B |
| AstraZeneca | 60.44B |
| Novartis AG | 56.58B |
| Novo Nordisk | 50.57B |
| Bristol-Myers Squibb Company | 48.48B |
| GSK plc | 43.29B |
SNY News
- 7 days ago - Sanofi: Information concerning the total number of voting rights and shares - April 2026 - GlobeNewsWire
- 7 days ago - Sanofi Reports Positive Phase 2 Data For Efdoralprin Alfa In AATD-Related Emphysema - Finanz Nachrichten
- 8 days ago - Sanofi (SNY) Presents Promising Phase 2 Study Results for Efdoralprin Alfa - GuruFocus
- 8 days ago - 1 Dirt Cheap Growth Stock to Buy Right Now - The Motley Fool
- 8 days ago - Sanofi reports ElevAATe trial of efdoralprin alfa meets primary endpoint - TheFly
- 8 days ago - Sanofi says rare lung disease drug outperforms standard care in trial - Reuters
- 8 days ago - Sanofi: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD - Finanz Nachrichten
- 8 days ago - Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD - GlobeNewsWire